Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
6.58
-0.12 (-1.79%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis.

Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

The company’s product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms.

It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand.

The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018.

Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Lyra Therapeutics, Inc.
Lyra Therapeutics logo
CountryUnited States
Founded2005
IPO DateMay 1, 2020
IndustryBiotechnology
SectorHealthcare
Employees30
CEOMaria Palasis

Contact Details

Address:
480 Arsenal Way
Watertown, Massachusetts 02472
United States
Phone617 393 4600
Websitelyratherapeutics.com

Stock Details

Ticker SymbolLYRA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code0001327273
CUSIP Number55234L105
ISIN NumberUS55234L1052
SIC Code3841

Key Executives

NamePosition
Dr. Maria Palasis Ph.D.Chief Executive Officer, President and Director
Dr. Harlan W. Waksal M.D.Executive Chairman
Jason CavalierChief Financial Officer, Treasurer and Secretary
Dr. Carmichael S. Roberts Jr., Ph.D.Co-Founder
Ronan P. O'Brien J.D.Chief Legal Officer
Vineeta Belanger Ph.D.Senior Vice President of Clinical Affairs
Dr. Robert Kern M.D.Chief Clinical Advisor
Gloria CosgroveSenior Vice President of Quality
Allison NanceSenior Vice President of Regulatory Affairs
Dr. Elazer R. Edelman FACC, M.D., Ph.D.Vice President of Finance and Risk

Latest SEC Filings

DateTypeTitle
Aug 1, 20258-KCurrent Report
Jul 31, 2025424B3Prospectus
Jul 30, 2025EFFECTNotice of Effectiveness
Jul 22, 2025S-1General form for registration of securities under the Securities Act of 1933
Jul 10, 2025144Filing
Jun 27, 20258-KCurrent Report
Jun 27, 2025424B5Filing
Jun 26, 2025424B5Filing
Jun 23, 20258-KCurrent Report
Jun 9, 20258-KCurrent Report